Auspex Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing novel medicines for orphan diseases. They develop a pipeline of therapeutics that improves on existing drugs across various therapeutic areas, including involuntary movement disorders, respiratory disease, and inflammation. Their product candidates address unmet medical needs in hyperkinetic movement disorders such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome, as well as other orphan indications. The company specializes in developing deuterated analogs of clinically-validated drugs to improve their efficacy and safety profiles.